Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Vaspin inhibits cytokine-induced nuclear factor-kappa B activation and adhesion molecule expression via AMP-activated protein kinase activation in vascular endothelial cells

Authors: Chang Hee Jung, Min Jung Lee, Yu Mi Kang, Yoo La Lee, Hae Kyeong Yoon, Sang-Wook Kang, Woo Je Lee, Joong-Yeol Park

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

Vaspin is an adipocytokine that was recently identified in the visceral adipose tissue of diabetic rats and has anti-diabetic and anti-atherogenic effects. We hypothesized that vaspin prevents inflammatory cytokine-induced nuclear factor-kappa B (NF-κB) activation by activating AMP-activated protein kinase (AMPK) in vascular endothelial cells.

Methods

We examined the effects of vaspin on NF-κB activation and the expression of the NF-κB-mediated genes intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and monocyte chemoattractant protein-1 (MCP-1). Human aortic endothelial cells (HAECS) were used. Tumor necrosis factor alpha (TNFα) was used as a representative proinflammatory cytokine.

Results

Treatment with vaspin significantly increased the phosphorylation of AMPK and acetyl-CoA carboxylase, the down-stream target of AMPK. Furthermore, treatment with vaspin significantly decreased TNFα-induced activation of NF-κB, as well as the expression of the adhesion molecules ICAM-1, VCAM-1, E-selectin, and MCP-1. These effects were abolished following transfection of AMPKα1-specific small interfering RNA. In an adhesion assay using THP-1 cells, vaspin reduced TNFα-induced adhesion of monocytes to HAECS in an AMPK-dependent manner.

Conclusions

Vaspin might attenuate the cytokine-induced expression of adhesion molecule genes by inhibiting NF-κB following AMPK activation.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Schiffrin EL, Canadian Institutes of Health Research Multidisciplinary Research Group on H: Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens. 2002, 15 (10 Pt 2): 115S-122S.CrossRefPubMed Schiffrin EL, Canadian Institutes of Health Research Multidisciplinary Research Group on H: Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens. 2002, 15 (10 Pt 2): 115S-122S.CrossRefPubMed
3.
go back to reference Allan LG: Is there a constant minimum perceptual duration?. Q J Exp Psychol. 1976, 28 (1): 71-76. 10.1080/14640747608400539.CrossRefPubMed Allan LG: Is there a constant minimum perceptual duration?. Q J Exp Psychol. 1976, 28 (1): 71-76. 10.1080/14640747608400539.CrossRefPubMed
4.
go back to reference Kutuk O, Basaga H: Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med. 2003, 9 (12): 549-557. 10.1016/j.molmed.2003.10.007.CrossRefPubMed Kutuk O, Basaga H: Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med. 2003, 9 (12): 549-557. 10.1016/j.molmed.2003.10.007.CrossRefPubMed
5.
go back to reference Galkina E, Ley K: Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007, 27 (11): 2292-2301. 10.1161/ATVBAHA.107.149179.CrossRefPubMed Galkina E, Ley K: Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007, 27 (11): 2292-2301. 10.1161/ATVBAHA.107.149179.CrossRefPubMed
6.
go back to reference Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D: Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996, 97 (7): 1715-1722. 10.1172/JCI118598.PubMedCentralCrossRefPubMed Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D: Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996, 97 (7): 1715-1722. 10.1172/JCI118598.PubMedCentralCrossRefPubMed
7.
go back to reference Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA: Role of nuclear factor-kappa B in atherogenesis. Exp Physiol. 1997, 82 (2): 297-304.CrossRefPubMed Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA: Role of nuclear factor-kappa B in atherogenesis. Exp Physiol. 1997, 82 (2): 297-304.CrossRefPubMed
8.
go back to reference Bourcier T, Sukhova G, Libby P: The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem. 1997, 272 (25): 15817-15824. 10.1074/jbc.272.25.15817.CrossRefPubMed Bourcier T, Sukhova G, Libby P: The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem. 1997, 272 (25): 15817-15824. 10.1074/jbc.272.25.15817.CrossRefPubMed
9.
go back to reference Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, Cybulsky MI: Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res. 1999, 85 (2): 199-207. 10.1161/01.RES.85.2.199.CrossRefPubMed Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, Cybulsky MI: Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res. 1999, 85 (2): 199-207. 10.1161/01.RES.85.2.199.CrossRefPubMed
10.
go back to reference Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998, 394 (6696): 894-897. 10.1038/29788.CrossRefPubMed Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998, 394 (6696): 894-897. 10.1038/29788.CrossRefPubMed
11.
12.
go back to reference Cybulsky MI, Gimbrone MA: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991, 251 (4995): 788-791. 10.1126/science.1990440.CrossRefPubMed Cybulsky MI, Gimbrone MA: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991, 251 (4995): 788-791. 10.1126/science.1990440.CrossRefPubMed
13.
go back to reference Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S: Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002, 51 (7): 2074-2081. 10.2337/diabetes.51.7.2074.CrossRefPubMed Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S: Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002, 51 (7): 2074-2081. 10.2337/diabetes.51.7.2074.CrossRefPubMed
14.
go back to reference Zou MH, Wu Y: AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol. 2008, 35 (5–6): 535-545.PubMedCentralCrossRefPubMed Zou MH, Wu Y: AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol. 2008, 35 (5–6): 535-545.PubMedCentralCrossRefPubMed
15.
go back to reference Hattori Y, Suzuki K, Hattori S, Kasai K: Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006, 47 (6): 1183-1188. 10.1161/01.HYP.0000221429.94591.72.CrossRefPubMed Hattori Y, Suzuki K, Hattori S, Kasai K: Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006, 47 (6): 1183-1188. 10.1161/01.HYP.0000221429.94591.72.CrossRefPubMed
16.
go back to reference Yamawaki H: Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011, 34 (3): 307-310. 10.1248/bpb.34.307.CrossRefPubMed Yamawaki H: Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011, 34 (3): 307-310. 10.1248/bpb.34.307.CrossRefPubMed
17.
go back to reference Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005, 102 (30): 10610-10615. 10.1073/pnas.0504703102.PubMedCentralCrossRefPubMed Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005, 102 (30): 10610-10615. 10.1073/pnas.0504703102.PubMedCentralCrossRefPubMed
18.
go back to reference Jung CH, Lee WJ, Hwang JY, Lee MJ, Seol SM, Kim YM, Lee YL, Kim HS, Kim MS, Park JY: Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLos One. 2012, 7 (12): e52346-10.1371/journal.pone.0052346.PubMedCentralCrossRefPubMed Jung CH, Lee WJ, Hwang JY, Lee MJ, Seol SM, Kim YM, Lee YL, Kim HS, Kim MS, Park JY: Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLos One. 2012, 7 (12): e52346-10.1371/journal.pone.0052346.PubMedCentralCrossRefPubMed
19.
go back to reference Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, Lee YL, Park JY: Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 2011, 413 (2): 264-269. 10.1016/j.bbrc.2011.08.083.CrossRefPubMed Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, Lee YL, Park JY: Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 2011, 413 (2): 264-269. 10.1016/j.bbrc.2011.08.083.CrossRefPubMed
20.
go back to reference Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A: Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes. 2012, 61 (11): 2823-2832. 10.2337/db12-0232.PubMedCentralCrossRefPubMed Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A: Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes. 2012, 61 (11): 2823-2832. 10.2337/db12-0232.PubMedCentralCrossRefPubMed
21.
go back to reference Hattori Y, Suzuki M, Hattori S, Kasai K: Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension. 2002, 39 (1): 22-28. 10.1161/hy1201.097300.CrossRefPubMed Hattori Y, Suzuki M, Hattori S, Kasai K: Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension. 2002, 39 (1): 22-28. 10.1161/hy1201.097300.CrossRefPubMed
22.
go back to reference Iwai K: Diverse ubiquitin signaling in NF-kappaB activation. Trends Cell Biol. 2012, 22 (7): 355-364. 10.1016/j.tcb.2012.04.001.CrossRefPubMed Iwai K: Diverse ubiquitin signaling in NF-kappaB activation. Trends Cell Biol. 2012, 22 (7): 355-364. 10.1016/j.tcb.2012.04.001.CrossRefPubMed
23.
go back to reference Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW: Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry. 2002, 41 (43): 12995-13002. 10.1021/bi0263210.CrossRefPubMed Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW: Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry. 2002, 41 (43): 12995-13002. 10.1021/bi0263210.CrossRefPubMed
24.
go back to reference Bess E, Fisslthaler B, Fromel T, Fleming I: Nitric oxide-induced activation of the AMP-activated protein kinase alpha2 subunit attenuates IkappaB kinase activity and inflammatory responses in endothelial cells. PLos One. 2011, 6 (6): e20848-10.1371/journal.pone.0020848.PubMedCentralCrossRefPubMed Bess E, Fisslthaler B, Fromel T, Fleming I: Nitric oxide-induced activation of the AMP-activated protein kinase alpha2 subunit attenuates IkappaB kinase activity and inflammatory responses in endothelial cells. PLos One. 2011, 6 (6): e20848-10.1371/journal.pone.0020848.PubMedCentralCrossRefPubMed
25.
go back to reference Malin DH, Lake JR, Shenoi M, Upchurch TP, Johnson SC, Schweinle WE, Cadle CD: The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl). 1998, 140 (3): 371-377. 10.1007/s002130050778.CrossRef Malin DH, Lake JR, Shenoi M, Upchurch TP, Johnson SC, Schweinle WE, Cadle CD: The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl). 1998, 140 (3): 371-377. 10.1007/s002130050778.CrossRef
26.
go back to reference Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A: Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltage-dependent anion channel complex. Circ Res. 2013, 112 (5): 771-780. 10.1161/CIRCRESAHA.111.300049.CrossRefPubMed Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A: Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltage-dependent anion channel complex. Circ Res. 2013, 112 (5): 771-780. 10.1161/CIRCRESAHA.111.300049.CrossRefPubMed
27.
go back to reference Hardie DG: The AMP-activated protein kinase pathway–new players upstream and downstream. J Cell Sci. 2004, 117 (Pt 23): 5479-5487.CrossRefPubMed Hardie DG: The AMP-activated protein kinase pathway–new players upstream and downstream. J Cell Sci. 2004, 117 (Pt 23): 5479-5487.CrossRefPubMed
28.
go back to reference Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, Winder WW: Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol. 2002, 92 (6): 2475-2482.CrossRefPubMed Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, Winder WW: Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol. 2002, 92 (6): 2475-2482.CrossRefPubMed
29.
go back to reference Phalitakul S, Okada M, Hara Y, Yamawaki H: Vaspin prevents TNF-alpha-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-kappaB and PKCtheta activation in cultured rat vascular smooth muscle cells. Pharmacol Res. 2011, 64 (5): 493-500. 10.1016/j.phrs.2011.06.001.CrossRefPubMed Phalitakul S, Okada M, Hara Y, Yamawaki H: Vaspin prevents TNF-alpha-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-kappaB and PKCtheta activation in cultured rat vascular smooth muscle cells. Pharmacol Res. 2011, 64 (5): 493-500. 10.1016/j.phrs.2011.06.001.CrossRefPubMed
30.
go back to reference Li H, Peng W, Zhuang J, Lu Y, Jian W, Wei Y, Li W, Xu Y: Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-kappaB signaling pathways. Atherosclerosis. 2013, 228 (1): 61-68. 10.1016/j.atherosclerosis.2013.02.013.CrossRefPubMed Li H, Peng W, Zhuang J, Lu Y, Jian W, Wei Y, Li W, Xu Y: Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-kappaB signaling pathways. Atherosclerosis. 2013, 228 (1): 61-68. 10.1016/j.atherosclerosis.2013.02.013.CrossRefPubMed
31.
go back to reference Sung JY, Choi HC: Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway. Vascul Pharmacol. 2012, 56 (1–2): 1-8.CrossRefPubMed Sung JY, Choi HC: Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway. Vascul Pharmacol. 2012, 56 (1–2): 1-8.CrossRefPubMed
32.
go back to reference Kim HJ, Park KG, Yoo EK, Kim YH, Kim YN, Kim HS, Kim HT, Park JY, Lee KU, Jang WG: Effects of PGC-1alpha on TNF-alpha-induced MCP-1 and VCAM-1 expression and NF-kappaB activation in human aortic smooth muscle and endothelial cells. Antioxid Redox Signal. 2007, 9 (3): 301-307. 10.1089/ars.2006.1456.CrossRefPubMed Kim HJ, Park KG, Yoo EK, Kim YH, Kim YN, Kim HS, Kim HT, Park JY, Lee KU, Jang WG: Effects of PGC-1alpha on TNF-alpha-induced MCP-1 and VCAM-1 expression and NF-kappaB activation in human aortic smooth muscle and endothelial cells. Antioxid Redox Signal. 2007, 9 (3): 301-307. 10.1089/ars.2006.1456.CrossRefPubMed
33.
go back to reference Chandrasekar B, Boylston WH, Venkatachalam K, Webster NJ, Prabhu SD, Valente AJ: Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression. J Biol Chem. 2008, 283 (36): 24889-24898. 10.1074/jbc.M804236200.PubMedCentralCrossRefPubMed Chandrasekar B, Boylston WH, Venkatachalam K, Webster NJ, Prabhu SD, Valente AJ: Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression. J Biol Chem. 2008, 283 (36): 24889-24898. 10.1074/jbc.M804236200.PubMedCentralCrossRefPubMed
34.
go back to reference Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D, Zou MH: AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res. 2010, 106 (6): 1117-1128. 10.1161/CIRCRESAHA.109.212530.PubMedCentralCrossRefPubMed Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D, Zou MH: AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res. 2010, 106 (6): 1117-1128. 10.1161/CIRCRESAHA.109.212530.PubMedCentralCrossRefPubMed
35.
go back to reference Li Z, Zhong Q, Yang T, Xie X, Chen M: The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs). Cardiovasc Diabetol. 2013, 12: 141-10.1186/1475-2840-12-141.PubMedCentralCrossRefPubMed Li Z, Zhong Q, Yang T, Xie X, Chen M: The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs). Cardiovasc Diabetol. 2013, 12: 141-10.1186/1475-2840-12-141.PubMedCentralCrossRefPubMed
36.
go back to reference Zhu M, Chen J, Jiang H, Miao C: Propofol protects against high glucose-induced endothelial adhesion molecules expression in human umbilical vein endothelial cells. Cardiovasc Diabetol. 2013, 12: 13-10.1186/1475-2840-12-13.PubMedCentralCrossRefPubMed Zhu M, Chen J, Jiang H, Miao C: Propofol protects against high glucose-induced endothelial adhesion molecules expression in human umbilical vein endothelial cells. Cardiovasc Diabetol. 2013, 12: 13-10.1186/1475-2840-12-13.PubMedCentralCrossRefPubMed
37.
go back to reference Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D: Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J. 2000, 346 (Pt 3): 659-669.PubMedCentralCrossRefPubMed Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D: Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J. 2000, 346 (Pt 3): 659-669.PubMedCentralCrossRefPubMed
38.
go back to reference Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA: Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci. 1999, 24 (1): 22-25. 10.1016/S0968-0004(98)01340-1.CrossRefPubMed Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA: Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci. 1999, 24 (1): 22-25. 10.1016/S0968-0004(98)01340-1.CrossRefPubMed
39.
go back to reference Davis BJ, Xie Z, Viollet B, Zou MH: Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006, 55 (2): 496-505. 10.2337/diabetes.55.02.06.db05-1064.CrossRefPubMed Davis BJ, Xie Z, Viollet B, Zou MH: Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006, 55 (2): 496-505. 10.2337/diabetes.55.02.06.db05-1064.CrossRefPubMed
40.
go back to reference Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH: Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004, 279 (42): 43940-43951. 10.1074/jbc.M404421200.CrossRefPubMed Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH: Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004, 279 (42): 43940-43951. 10.1074/jbc.M404421200.CrossRefPubMed
41.
go back to reference Hausenloy DJ: Drug discovery possibilities from visfatin cardioprotection?. Curr Opin Pharmacol. 2009, 9 (2): 202-207. 10.1016/j.coph.2008.10.005.CrossRefPubMed Hausenloy DJ: Drug discovery possibilities from visfatin cardioprotection?. Curr Opin Pharmacol. 2009, 9 (2): 202-207. 10.1016/j.coph.2008.10.005.CrossRefPubMed
42.
go back to reference Choi SH, Hong ES, Lim S: Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol. 2013, 4: 97.CrossRef Choi SH, Hong ES, Lim S: Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol. 2013, 4: 97.CrossRef
43.
go back to reference Phalitakul S, Okada M, Hara Y, Yamawaki H: Vaspin prevents methylglyoxal-induced apoptosis in human vascular endothelial cells by inhibiting reactive oxygen species generation. Acta Physiol. 2013, 209 (3): 212-219. Phalitakul S, Okada M, Hara Y, Yamawaki H: Vaspin prevents methylglyoxal-induced apoptosis in human vascular endothelial cells by inhibiting reactive oxygen species generation. Acta Physiol. 2013, 209 (3): 212-219.
44.
go back to reference Phalitakul S, Okada M, Hara Y, Yamawaki H: A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem Biophys Res Commun. 2012, 423 (4): 844-849. 10.1016/j.bbrc.2012.06.052.CrossRefPubMed Phalitakul S, Okada M, Hara Y, Yamawaki H: A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem Biophys Res Commun. 2012, 423 (4): 844-849. 10.1016/j.bbrc.2012.06.052.CrossRefPubMed
45.
go back to reference Cho JK, Han TK, Kang HS: Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur J Appl Physiol. 2010, 108 (2): 347-353. 10.1007/s00421-009-1238-8.CrossRefPubMed Cho JK, Han TK, Kang HS: Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur J Appl Physiol. 2010, 108 (2): 347-353. 10.1007/s00421-009-1238-8.CrossRefPubMed
46.
go back to reference Kim JM, Kim TN, Won JC: Association between serum vaspin level and metabolic syndrome in healthy Korean subjects. Metab Syndr Relat Disord. 2013, 11 (6): 385-391. 10.1089/met.2013.0054.CrossRefPubMed Kim JM, Kim TN, Won JC: Association between serum vaspin level and metabolic syndrome in healthy Korean subjects. Metab Syndr Relat Disord. 2013, 11 (6): 385-391. 10.1089/met.2013.0054.CrossRefPubMed
47.
go back to reference Koiou E, Tziomalos K, Dinas K, Katsikis I, Kalaitzakis E, Delkos D, Kandaraki EA, Panidis D: The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr J. 2011, 58 (4): 237-246. 10.1507/endocrj.K10E-330.CrossRefPubMed Koiou E, Tziomalos K, Dinas K, Katsikis I, Kalaitzakis E, Delkos D, Kandaraki EA, Panidis D: The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr J. 2011, 58 (4): 237-246. 10.1507/endocrj.K10E-330.CrossRefPubMed
48.
go back to reference Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS: Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes. 2008, 57 (6): 1501-1507. 10.2337/db08-0127.CrossRefPubMed Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS: Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes. 2008, 57 (6): 1501-1507. 10.2337/db08-0127.CrossRefPubMed
49.
go back to reference Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M: Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008, 57 (2): 372-377.CrossRefPubMed Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M: Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008, 57 (2): 372-377.CrossRefPubMed
50.
go back to reference Zhang B, Peng W, Li H, Lu Y, Zhuang J, Wang K, Su Y, Xu Y: Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions. Clin Biochem. 2013, 46 (15): 1520-1525. 10.1016/j.clinbiochem.2013.06.028.CrossRefPubMed Zhang B, Peng W, Li H, Lu Y, Zhuang J, Wang K, Su Y, Xu Y: Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions. Clin Biochem. 2013, 46 (15): 1520-1525. 10.1016/j.clinbiochem.2013.06.028.CrossRefPubMed
51.
go back to reference Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, Jang HC, Kim MS: Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol (Oxf). 2011, 75 (5): 628-635. 10.1111/j.1365-2265.2011.04095.x.CrossRef Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, Jang HC, Kim MS: Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol (Oxf). 2011, 75 (5): 628-635. 10.1111/j.1365-2265.2011.04095.x.CrossRef
52.
go back to reference Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, Lampropoulos S: Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta. 2011, 412 (1-2): 48-52. 10.1016/j.cca.2010.09.012.CrossRefPubMed Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, Lampropoulos S: Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta. 2011, 412 (1-2): 48-52. 10.1016/j.cca.2010.09.012.CrossRefPubMed
53.
go back to reference Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A: Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. J Clin Endocrinol Metab. 2012, 97 (7): E1202-1207. 10.1210/jc.2011-3297.CrossRefPubMed Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A: Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. J Clin Endocrinol Metab. 2012, 97 (7): E1202-1207. 10.1210/jc.2011-3297.CrossRefPubMed
54.
go back to reference Wada J: Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs. 2008, 17 (3): 327-333. 10.1517/13543784.17.3.327.CrossRefPubMed Wada J: Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs. 2008, 17 (3): 327-333. 10.1517/13543784.17.3.327.CrossRefPubMed
Metadata
Title
Vaspin inhibits cytokine-induced nuclear factor-kappa B activation and adhesion molecule expression via AMP-activated protein kinase activation in vascular endothelial cells
Authors
Chang Hee Jung
Min Jung Lee
Yu Mi Kang
Yoo La Lee
Hae Kyeong Yoon
Sang-Wook Kang
Woo Je Lee
Joong-Yeol Park
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-13-41

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.